A case in which a shareholder has accused a pharmaceutical company of downplaying the dangers of using its drug to treat liver conditions is set to proceed in the District of Delaware.

The complaint transferred into the court Thursday and originally filed Dec. 29 argues that by underemphasizing the risks of Ocaliva, Intercept Pharmaceuticals Inc. put the drug’s marketability in jeopardy, led to shares decreasing in value by nearly 59% and made the FDA more likely to both investigate the drug further and turn down an application for it to be used to treat another liver disease.